Nurix Therapeutics (NRIX) Assets Average (2020 - 2026)

Nurix Therapeutics (NRIX) has 7 years of Assets Average data on file, last reported at $585.8 million in Q2 2026.

• On a quarterly basis, Assets Average fell 2.89% year-over-year to $585.8 million in Q2 2026; TTM through May 2026 was $585.8 million, a 2.89% decrease from a year earlier, with the FY2025 full-year figure at $678.7 million, up 32.44% from the prior year.
• Assets Average for Q2 2026 stood at $585.8 million, down from $662.1 million in the prior quarter.
• Over the last five years, Assets Average for NRIX reached as high as $662.1 million in Q1 2026 and fell as low as $329.4 million in Q3 2023.
• Historically, Assets Average has averaged $481.0 million across 5 years, with a median of $447.6 million in 2022.
• Across the five-year window, Assets Average fell 24.23% in 2023 and jumped 92.2% in 2025, its largest moves.
• Year by year, Assets Average stood at $438.0 million in 2022, then fell by 24.23% to $331.9 million in 2023, then surged by 78.21% to $591.5 million in 2024, then grew by 2.34% to $605.3 million in 2025, then retreated by 3.22% to $585.8 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $585.8 million in Q2 2026, $662.1 million in Q1 2026, and $605.3 million in Q4 2025.